Evidence map›Paper›PMID 29941557›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2018

Focal, remote-controlled, chronic chemical modulation of brain microstructures.

Khalil B Ramadi, Canan Dagdeviren, Kevin C Spencer, Pauline Joe, Max Cotler, Erin Rousseau, Carlos Nunez-Lopez, Ann M Graybiel, Robert Langer, Michael J Cima

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Khalil B RamadiKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139.ORCID 0000-0002-5864-2386
Canan DagdevirenMedia Lab, Massachusetts Institute of Technology, Cambridge, MA 02139.
Kevin C SpencerKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139.
Pauline JoeKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139.
Max CotlerKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139.
Erin RousseauKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139.
Carlos Nunez-LopezKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139.ORCID 0000-0001-9859-8562
Ann M GraybielMcGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, MA 02139.
Robert LangerKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139; rlanger@mit.edu mjcima@mit.edu.ORCID 0000-0003-4255-0492
Michael J CimaKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139; rlanger@mit.edu mjcima@mit.edu.
Massachusetts Institute of Technology · USMcGovern Institute for Brain Research · US

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Paula T Hammond · 1985 to 2026
$93.9M
A New Device for Electrical & Chemical Modulation of Pathological Neural ActivityR01EB016101 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI CIMA, MICHAEL J, GRAYBIEL, ANN M · 2013 to 2017
$5.5M
NCI NIH HHS P30 CA014051NIBIB NIH HHS R01 EB016101
6 · The paper itself

Abstract

Direct delivery of fluid to brain parenchyma is critical in both research and clinical settings. This is usually accomplished through acutely inserted cannulas. This technique, however, results in backflow and significant dispersion away from the infusion site, offering little spatial or temporal control in delivering fluid. We present an implantable, MRI-compatible, remotely controlled drug delivery system for minimally invasive interfacing with brain microstructures in freely moving animals. We show that infusions through acutely inserted needles target a region more than twofold larger than that of identical infusions through chronically implanted probes due to reflux and backflow. We characterize the dynamics of in vivo infusions using positron emission tomography techniques. Volumes as small as 167 nL of copper-64 and fludeoxyglucose labeled agents are quantified. We further demonstrate the importance of precise drug volume dosing to neural structures to elicit behavioral effects reliably. Selective modulation of the substantia nigra, a critical node in basal ganglia circuitry, via muscimol infusion induces behavioral changes in a volume-dependent manner, even when the total dose remains constant. Chronic device viability is confirmed up to 1-y implantation in rats. This technology could potentially enable precise investigation of neurological disease pathology in preclinical models, and more efficacious treatment in human patients.

Indexed as

Drug Delivery SystemsAnimalsBasal GangliaCopperFluorodeoxyglucose F18Magnetic Resonance ImagingRatsSubstantia NigraCopperFluorodeoxyglucose F18braindrug deliveryneural implantPETsubstantia nigra

Identifiers

PMID29941557
PMCPMC6048526
OpenAlexW2810127067

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.